BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06058156 (SAR444656 in Moderate to Severe Atopic Dermatitis): BVCT ex-ante prediction vs. reported outcome

On 4 Nov 2024, BioinvestGPT's BVCT predicted technical success and commercial partial success for this trial. The 25 Jun 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically TBD and commercially insufficient.

Clinical Trial

NCTID
NCT06058156
Acronym
ADVANTA
Drug Name
SAR444656 (KT-474)
Drug MoA
E3ligase-binding IRAK4 degrader
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Skin and Connective Tissue Diseases
Indication
Moderate to Severe Atopic Dermatitis
Human Patients
70
Sponsor
Kymera Therapeutics / Sanofi
Phase
Phase 2

Prediction of , index 1822

Prospective Prediction
Prediction Index
1822
Prediction Date
Commercial Prediction
partial SUCCESS (commercially maybe sufficient clinical benefit in EASI75 superior to adalimumab and non-superior to upadacitinib)
Technical Prediction
SUCCESS (statistically significant clinical benefit in EASI75 against placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
233 days in advance
Readout Data Interpretation
SAR444656’s further development is discontinued
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically TBD and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
Phase
Phase 2
Status
Terminated
Enrollment
70
Lead sponsor
Sanofi
Conditions
Atopic Dermatitis
Interventions
DRUG: SAR444656 (KT-474); DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2023-11-09
Primary completion
2025-10-23
Completion
2025-11-20
Primary outcomes
  • Percent change from baseline in EASI (Week 16)

NCT06058156 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials